News & Events

EUROGIN, 15-18 June 2016, Salzburg, Austria

On Jun 02, 2016

Visit SYNLAB at EUROGIN 2016, the leading European meeting for Cervical Cancer Prevention.

EUROGIN, 15-18 June 2016, Salzburg, Austria
The leading European meeting for Cervical Cancer Prevention

On May 31, 2016
You are wellcome to visit us at SYNLAB – Neumann Booth 16, Exhibition Area


Do not miss the oral presentation about the new sel-sampling HPV test evaluated in the TRACE clinical trial conducted by Neumann Ltd. in collaboration with SYNLAB GenoID Laboratory:

Marta Benczik, MD
CONFIDENCE™ HPV TEST VALIDATION FOR QVINTIP® SELF-COLLECTED VAGINAL SAMPLE  

OC 12 – Current knowledge on HPV sampling
FRIDAY, June 17, 2016
Session starts at 17.45


Be there at the oral presentation about the breaking new methylation biomarker test for HPV triage evaluated in the TRACE clinical trial conducted by Neumann Ltd. in collaboration with SYNLAB GenoID Laboratory:

Adrienn Kocsis, MD
PERFORMANCE OF A NEW HPV AND BIOMARKER ASSAY IN THE MANAGENET OF HIGH RISK HPV POSITIVE CASES

OC 11 – New insights on molecular biology and markers
FRIDAY, June 17, 2016
Session starts at 17.45

 

Message from the honorary presidents of EUROGIN 2016

„It is with great pleasure that we welcome you at EUROGIN 2016 in Salzburg, Austria…

The annual edition of EUROGIN is a great reminder of what basic and clinical sciences have achieved to date in the battle against cervical cancer - a leading cause of death in women worldwide. During the past two decades EUROGIN has furthermore been an excellent platform to communicate and discuss findings about the entire spectrum of human papillomavirus (HPV) related diseases.

One highlight of the recent past was the FDA and EMA approval of the nona-valent HPV vaccine, which represents an important step in the final elimination of cervical cancer if vaccination coverage significantly improves globally.

A new era of cervical cancer screening had begun when the FDA approved an HPV test for primary cervical cancer screening in the US. This opened the door for an entire array of new debates including the lengths of the respective screening intervals, at what age of the woman screening should begin and end, and finally what the triage strategy should be. In 2015 the Netherlands and Australia approved primary HPV testing to be integrated in their screening programs. As a consequence an increasing number of screening tests are being developed, including cellular markers for detection of underlying disease. The common believe is that cervical cancer screening is continuously developing towards the usage of molecular markers opening the gateway for personalized medicine, which will compete with the performance of cytology-based methods.
Finally, the development of novel therapeutic vaccines that are currently tested in clinical trials represents a significant step in improving cervical cancer treatment options, which hasn’t seen major advances in the past decades…”

Thomas Iftner
Elmar Jour
Congress Presidents